These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 15199074)
81. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084 [TBL] [Abstract][Full Text] [Related]
82. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909 [TBL] [Abstract][Full Text] [Related]
83. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Bailey TC; Little JR; Littenberg B; Reichley RM; Dunagan WC Clin Infect Dis; 1997 May; 24(5):786-95. PubMed ID: 9142771 [TBL] [Abstract][Full Text] [Related]
84. An aminoglycoside dosing program using the Casio FX-700P pocket computer. Yutani RM Hosp Pharm; 1985 Jun; 20(6):416, 421-3, 426. PubMed ID: 10278328 [TBL] [Abstract][Full Text] [Related]
85. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Streetman DS; Nafziger AN; Destache CJ; Bertino AS Pharmacotherapy; 2001 Apr; 21(4):443-51. PubMed ID: 11310518 [TBL] [Abstract][Full Text] [Related]
86. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Rougier F; Claude D; Maurin M; Sedoglavic A; Ducher M; Corvaisier S; Jelliffe R; Maire P Antimicrob Agents Chemother; 2003 Mar; 47(3):1010-6. PubMed ID: 12604535 [TBL] [Abstract][Full Text] [Related]
87. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
88. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. Pathak AS; Pacificar JS; Shapiro CE; Williams SG J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298 [TBL] [Abstract][Full Text] [Related]
90. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. Lucena MI; Andrade RJ; Cabello MR; Hidalgo R; Gonzalez-Correa JA; Sanchez de la Cuesta F J Hepatol; 1995 Feb; 22(2):189-96. PubMed ID: 7790708 [TBL] [Abstract][Full Text] [Related]
91. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Burton ME; Ash CL; Hill DP; Handy T; Shepherd MD; Vasko MR Clin Pharmacol Ther; 1991 Jun; 49(6):685-94. PubMed ID: 1905602 [TBL] [Abstract][Full Text] [Related]
92. [Cost-effectiveness analysis of active TDM in elderly patients treated with aminoglycosides]. Leon-Djian CB; Bourguignon L; Späth HM; Maire P Therapie; 2011; 66(5):445-52. PubMed ID: 22031689 [TBL] [Abstract][Full Text] [Related]
93. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Barclay ML; Duffull SB; Begg EJ; Buttimore RC Aust N Z J Med; 1995 Jun; 25(3):230-5. PubMed ID: 7487691 [TBL] [Abstract][Full Text] [Related]
94. Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults. LeBras M; Chow I; Mabasa VH; Ensom MH Neurocrit Care; 2016 Dec; 25(3):492-507. PubMed ID: 27043949 [TBL] [Abstract][Full Text] [Related]
95. Aminoglycoside nephrotoxicity. Rougier F; Claude D; Maurin M; Maire P Curr Drug Targets Infect Disord; 2004 Jun; 4(2):153-62. PubMed ID: 15180462 [TBL] [Abstract][Full Text] [Related]
96. Once-daily dosing of gentamicin: experience with therapeutic drug monitoring and Bayesian pharmacokinetics. Klotz U; Godel A Ther Drug Monit; 1994 Oct; 16(5):534-5. PubMed ID: 7846756 [No Abstract] [Full Text] [Related]
97. Determination of the optimum timing for pharmacokinetic monitoring of once daily aminoglycoside dosing. Brown G; McCormack JP Intensive Care Med; 1994; 20(3):243-4. PubMed ID: 8014297 [No Abstract] [Full Text] [Related]
98. Studies of risk factors for aminoglycoside nephrotoxicity. Smith CR; Moore RD; Lietman PS Am J Kidney Dis; 1986 Nov; 8(5):308-13. PubMed ID: 3538855 [TBL] [Abstract][Full Text] [Related]
99. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Ali MZ; Goetz MB Clin Infect Dis; 1997 May; 24(5):796-809. PubMed ID: 9142772 [TBL] [Abstract][Full Text] [Related]
100. Is aminoglycoside-associated nephrotoxicity uncommon in the U.K? Bailie GR; Mathews A J Clin Pharm Ther; 1987 Dec; 12(6):389-92. PubMed ID: 3440812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]